Henlius Starts First-in-Human Trial of Novel KAT6A/B Inhibitor HLX97 in Advanced Tumours

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.

Shanghai Henlius Biotech has begun dosing the first patient in a phase 1 clinical trial of HLX97, its independently developed KAT6A/B small molecule inhibitor, in patients with advanced or metastatic solid tumours in mainland China. The study, conducted across multiple centres, is designed to assess safety, tolerability, pharmacokinetics and preliminary antitumor activity as the candidate moves through dose-escalation and dose-expansion stages.

The trial will test HLX97 as a monotherapy and in combination with fulvestrant in HR-positive, HER2-negative locally advanced or metastatic breast cancer, targeting resistance to endocrine therapy linked to KAT6A amplification. With no KAT6A/B inhibitors yet approved globally, this programme positions Henlius at the forefront of a new epigenetic oncology class, although the company cautions that successful development and commercialisation of HLX97 remain uncertain for investors and other stakeholders.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on developing innovative therapies, including small molecule inhibitors and biologics, for oncology indications. Listed in Hong Kong, the company targets unmet medical needs in advanced and metastatic cancers, with a growing pipeline aimed at solid tumours and breast cancer in particular.

Average Trading Volume: 934,733

Technical Sentiment Signal: Buy

Current Market Cap: HK$39.13B

See more insights into 2696 stock on TipRanks’ Stock Analysis page.